Physician profile
Eric Christopher Shafer
NPI 1083804280
$3,610.18
in general payments reported to CMS, 2019-2025
23 companies · $677 in 2025
The $677 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $114 · 2021: $340 · 2022: $933 · 2023: $830 · 2024: $717 · 2025: $677.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,204 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,203.67 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,189.96 | 2021-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems, Amplatzer Amulet |
| Novartis Pharmaceuticals Corporation | $483.73 | 2021-2025 | |
| Abiomed | $230.06 | 2022-2024 | Impella |
| Boston Scientific Corporation | $219.89 | 2022-2025 | Watchman Flx, Watchman |
| Medtronic, INC. | $202.52 | 2021-2023 | Chameleon |
| E.R. Squibb & Sons, L.L.C. | $176.50 | 2022-2024 | Camzyos, Eliquis |
| Atricure, INC. | $172.68 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $123.60 | 2023 | Uptravi, Opsumit |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $113.66 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $109.63 | 2022-2024 | |
| Impulse Dynamics (USA) INC. | $97.91 | 2024-2025 | Optimizer |
| Astrazeneca Pharmaceuticals LP | $97.09 | 2021-2023 | Farxiga |
| Merck Sharp & Dohme LLC | $92.44 | 2021-2025 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.36 | 2024-2025 | Jardiance |
| Scpharmaceuticals INC. | $49.37 | 2023-2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $33.88 | 2022 | |
| Amgen INC. | $32.37 | 2024-2025 | Repatha |
| Pfizer INC. | $29.59 | 2023-2024 | |
| Edwards Lifesciences Corporation | $28.36 | 2024 | Sapien 3 Ultra Resilia |
| Alnylam Pharmaceuticals INC. | $19.21 | 2025 | Onpattro |
| Shockwave Medical, INC | $17.74 | 2021 | |
| Biotronik INC. | $14.05 | 2022 | |
| Daiichi Sankyo INC. | $13.58 | 2024 | Injectafer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Shafer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.